Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients
Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients
复制标题
DOI：
10.1002/ijc.22472
复制
发表时间：
2007-04-15
影响因子：
6.4
通讯作者：
Toda, Masahiro
中科院分区：
文献类型：
--
作者：
Ueda, Ryo;Yoshida, Kazunari;Toda, Masahiro
我们之前报道过使用睾丸 cDNA 文库通过血清学筛选将 SOX5 鉴定为神经胶质瘤抗原。本研究旨在分析胶质瘤患者中 SOX5 的表达、其免疫反应性以及 SOX5 IgG 反应与临床特征之间的相关性，以评估其作为诊断标志物的可能性。定量RT-PCR和Western blot分析显示SOX5在神经胶质瘤组织中表达，但在正常成人组织中不表达，睾丸除外。免疫组织化学分析显示，SOX5在胶质瘤细胞中表达，但在大脑皮层的非肿瘤组织中仅检测到少数SOX5阳性细胞。在 27 名神经胶质瘤患者中的 8 名（27.6%）、14 名其他脑部疾病患者中的 0 名（0%）、54 名其他癌症患者中的 1 名（1.9%）和 37 名健康个体中的 1 名（2.7%）的血清中检测到了针对 SOX5 的 IgG 抗体。对 SOX5 表现出 IgG 反应的胶质母细胞瘤 (GBM) 患者比没有 SOX5 抗体的 GBM 患者表现出明显更长的生存期。总之，SOX5在神经胶质瘤中异常表达，并且可以使用神经胶质瘤患者血清中的IgG将其识别为神经胶质瘤抗原。此外，SOX5 IgG 的存在与 GBM 患者的生存率之间存在统计学上显着的相关性，这表明神经胶质瘤抗原 SOX5 不仅可以用作诊断标记物，而且可以用作神经胶质瘤患者的预后标记物。 (c) 2007 年 Wiley-Liss, Inc.
We previously reported to identify SOX5 as a glioma antigen by serological screening using a testis cDNA library. The present study was designed to analyze SOX5 expression, its immunoreactivity, and the correlation between SOX5 IgG responses and clinical features in glioma patients to evaluate the possibility of its use as a diagnostic marker. Quantitative RT-PCR and Western blot analysis revealed that SOX5 was expressed in glioma tissues, but not in normal adult tissues, except in the testis. An immunohistochemical analysis showed that SOX5 was expressed in glioma cells, but only a few SOX5-positive cells were detected in non-neoplastic tissues from the cerebral cortex. IgG antibodies against SOX5 were detected in sera from 8 of the 27 glioma patients (27.6%), 0 of the 14 patients with other brain diseases (0%), 1 of the 54 other cancer patients (1.9%) and I of the 37 healthy individuals (2.7%). Patients with glioblastoma (GBM) who showed IgG responses against SOX5 exhibited significantly better survival periods than GBM patients without SOX5 antibodies. In summary, SOX5 is aberrantly expressed in glioma and can be recognized as a glioma antigen using IgGs from the sera of glioma patients. Furthermore, there is a statistically significant correlation between the presence of SOX5 IgGs and survival in GBM patients, suggesting that the glioma antigen SOX5 may be useful not only as a diagnostic marker, but also as a prognositic marker in glioma patients. (c) 2007 Wiley-Liss, Inc.